ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Following the opening of a 2,200 m2 cell and gene therapy facility in Boston last year, Takeda Pharmaceutical says it will spend $126 million to expand and renovate a facility on the other coast, in Thousand Oaks, California. Described in a press release as a move to “increase the site’s capacity to manufacture additional products for the rare disease community,” the project will add a 1,400 m2 facility to the current 1,300 m2 operation. Takeda says the plant will use automation, digitalization, and virtual reality training.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X